Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).
ResMed Inc. has disclosed that Chief Executive Officer and Director Michael J. Farrell intends to sell 4,991 shares of the company’s common stock on or about January 7, 2026, through Fidelity Brokerage Services LLC, under a Rule 144 filing. The shares, valued at roughly $1.24 million based on the filing’s aggregate market value, were acquired via stock options granted in November 2019 and exercised for cash, and follow Farrell’s prior open-market sales of a total of 16,020 shares in October and November 2025, signaling continued executive share disposals that may draw investor attention to insider selling activity and capital management at the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a U.S.-based medical technology company focused on developing and manufacturing devices and software solutions for sleep-disordered breathing and other chronic respiratory conditions. Its primary products include CPAP machines, ventilators, masks, and cloud-connected monitoring platforms used by sleep clinics, hospitals, and home-care providers worldwide, with a strong presence in the obstructive sleep apnea and respiratory care markets.
Average Trading Volume: 1,169,693
Technical Sentiment Signal: Buy
Current Market Cap: A$54.12B
See more insights into RMD stock on TipRanks’ Stock Analysis page.